DBV Technologies S.A. - American Depositary Shares (DBVT)
7.6000
-0.1000 (-1.30%)
NASDAQ · Last Trade: Apr 3rd, 12:37 PM EDT
Detailed Quote
Previous Close
7.700
Open
7.550
Bid
7.600
Ask
7.800
Day's Range
7.260 - 7.800
52 Week Range
0.4409 - 8.500
Volume
74,051
Market Cap
418.73M
PE Ratio (TTM)
-7.238
EPS (TTM)
-1.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,026,511
About DBV Technologies S.A. - American Depositary Shares (DBVT)
Dbv Technologies is a biopharmaceutical company focused on developing innovative therapies for patients with food allergies, particularly peanut allergies. Utilizing its proprietary Systemic Immunotherapy platform, the company aims to create treatments that help desensitize individuals to allergens, ultimately enhancing their quality of life and reducing the risk of severe allergic reactions. By leveraging advanced medical technology and a rigorous clinical development approach, Dbv Technologies strives to bring novel, breakthrough solutions to the field of immunotherapy for food allergies. Read More
DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research.
DBV Technologies secures FDA guidance for Accelerated Approval of its Viaskin Peanut patch, advancing treatment for toddlers with peanut allergies through pivotal trials.
DBV Technologies progresses with regulatory efforts for its Viaskin Peanut patch in the U.S. and Europe, while financial concerns loom as the company seeks additional funding to continue its operations.
